SCHEMBL3800513

SCHEMBL3800513

Nc1ccc(-c2c(N)cccc2Oc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCOA1 Q15788 1/20 0.53
NCOA3 Q9Y6Q9 1/20 0.53
MAOA P21397 1/20 0.52
BRD4 O60885 1/20 0.45
ALDH1A1 P00352 4/20 0.44
GAA P10253 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MITF O75030 1/20 0.44
MAPT P10636 1/20 0.44
GFER P55789 1/20 0.44
NLRP1 Q9C000 1/20 0.44
NOD2 Q9HC29 1/20 0.44
IKBKB O14920 1/20 0.44
BRAF P15056 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
NLRP3 Q96P20 1/20 0.43
MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25135315 0.93 NCOA1 (0.62) NCOA1NCOA3MAOABRD4ALDH1A1
SCHEMBL3789240 0.91 NCOA1 (0.49) NCOA1NCOA3MAOABRD4ALDH1A1
SCHEMBL10907085 0.84 NCOA1 (0.68) NCOA1NCOA3MAOAALDH1A1GAA
SCHEMBL3789550 0.83 MAOB (0.53) NCOA1NCOA3MAOABRD4ALDH1A1
SCHEMBL25135310 0.83 MAOB (0.58) NCOA1NCOA3MAOABRD4ALDH1A1
SCHEMBL4965452 0.81 ALDH1A1 (0.43) NCOA1NCOA3MAOABRD4ALDH1A1
SCHEMBL10703670 0.79 NCOA1 (0.57) NCOA1NCOA3MAOABRD4ALDH1A1
SCHEMBL3790679 0.79 NCOA1 (0.47) NCOA1NCOA3MAOABRD4ALDH1A1
SCHEMBL25135312 0.78 KDM4E (0.47) NCOA1NCOA3MAOABRD4ALDH1A1
Aniline SCHEMBL22169197 0.77 MAOA (0.58) NCOA1NCOA3MAOAALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
US-7405231-B2 Anticancer agents; inhibitors of the HER-signaling pathway with decreased toxicity, better solubility and improved pharmacokinetic profile; e.g. 1-[4-(4-(2-[(E)-2-(4-Methanesulfinyl-phenyl)-vinyl]-oxazol-4-ylmethoxy)-phenyl)-butyl]-1H-[1,2,3]triazole HOFFMANN-LA ROCHE INC. (US) 2008-07-29 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed
US-7235574-B2 Pentafluorosulfanyl compounds HOFFMANN-LA ROCHE INC. (US) 2007-06-26 US disclosed
US-20050203064-A1 Novel oxidized thioether derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-09-15 US disclosed
US-20050197370-A1 Novel pentafluorosulfanyl compounds HOFFMANN-LA ROCHE INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197370-A1 Novel pentafluorosulfanyl compounds SF3B5, SF3B1, SF3B3 NCOA1 723/4885NCOA3 556/4885MAOA 4144/4885
US-20050203064-A1 Novel oxidized thioether derivatives SULT1E1, CYP4F3, GPX4 NCOA1 603/4885NCOA3 600/4885MAOA 2877/4885
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 NCOA1 2120/4885NCOA3 989/4885MAOA 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.